263 related articles for article (PubMed ID: 30688548)
1. Gene Therapy for Inherited Retinal Degeneration.
Arbabi A; Liu A; Ameri H
J Ocul Pharmacol Ther; 2019 Mar; 35(2):79-97. PubMed ID: 30688548
[TBL] [Abstract][Full Text] [Related]
2. In Vivo CRISPR/Cas9-Mediated Genome Editing Mitigates Photoreceptor Degeneration in a Mouse Model of X-Linked Retinitis Pigmentosa.
Hu S; Du J; Chen N; Jia R; Zhang J; Liu X; Yang L
Invest Ophthalmol Vis Sci; 2020 Apr; 61(4):31. PubMed ID: 32330228
[TBL] [Abstract][Full Text] [Related]
3. Gene editing prospects for treating inherited retinal diseases.
Benati D; Patrizi C; Recchia A
J Med Genet; 2020 Jul; 57(7):437-444. PubMed ID: 31857428
[TBL] [Abstract][Full Text] [Related]
4. Genome-Editing Strategies for Treating Human Retinal Degenerations.
Quinn J; Musa A; Kantor A; McClements ME; Cehajic-Kapetanovic J; MacLaren RE; Xue K
Hum Gene Ther; 2021 Mar; 32(5-6):247-259. PubMed ID: 32993386
[TBL] [Abstract][Full Text] [Related]
5. CRISPR-Cas9 genome engineering: Treating inherited retinal degeneration.
Burnight ER; Giacalone JC; Cooke JA; Thompson JR; Bohrer LR; Chirco KR; Drack AV; Fingert JH; Worthington KS; Wiley LA; Mullins RF; Stone EM; Tucker BA
Prog Retin Eye Res; 2018 Jul; 65():28-49. PubMed ID: 29578069
[TBL] [Abstract][Full Text] [Related]
6. Induced Pluripotent Stem Cells and Genome-Editing Tools in Determining Gene Function and Therapy for Inherited Retinal Disorders.
Benati D; Leung A; Perdigao P; Toulis V; van der Spuy J; Recchia A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499601
[TBL] [Abstract][Full Text] [Related]
7. In Vivo CRISPR/Cas9 Gene Editing Corrects Retinal Dystrophy in the S334ter-3 Rat Model of Autosomal Dominant Retinitis Pigmentosa.
Bakondi B; Lv W; Lu B; Jones MK; Tsai Y; Kim KJ; Levy R; Akhtar AA; Breunig JJ; Svendsen CN; Wang S
Mol Ther; 2016 Mar; 24(3):556-63. PubMed ID: 26666451
[TBL] [Abstract][Full Text] [Related]
8. Application of CRISPR/Cas9 technologies combined with iPSCs in the study and treatment of retinal degenerative diseases.
Cai B; Sun S; Li Z; Zhang X; Ke Y; Yang J; Li X
Hum Genet; 2018 Sep; 137(9):679-688. PubMed ID: 30203114
[TBL] [Abstract][Full Text] [Related]
9. New Editing Tools for Gene Therapy in Inherited Retinal Dystrophies.
Pulman J; Sahel JA; Dalkara D
CRISPR J; 2022 Jun; 5(3):377-388. PubMed ID: 35506982
[TBL] [Abstract][Full Text] [Related]
10. Ocular delivery of CRISPR/Cas genome editing components for treatment of eye diseases.
Yu W; Wu Z
Adv Drug Deliv Rev; 2021 Jan; 168():181-195. PubMed ID: 32603815
[TBL] [Abstract][Full Text] [Related]
11. Genome Editing as a Treatment for the Most Prevalent Causative Genes of Autosomal Dominant Retinitis Pigmentosa.
Diakatou M; Manes G; Bocquet B; Meunier I; Kalatzis V
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126147
[No Abstract] [Full Text] [Related]
12. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
[TBL] [Abstract][Full Text] [Related]
13. Tissue-Specific Delivery of CRISPR Therapeutics: Strategies and Mechanisms of Non-Viral Vectors.
Shalaby K; Aouida M; El-Agnaf O
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33027946
[TBL] [Abstract][Full Text] [Related]
14. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration.
Burnight ER; Gupta M; Wiley LA; Anfinson KR; Tran A; Triboulet R; Hoffmann JM; Klaahsen DL; Andorf JL; Jiao C; Sohn EH; Adur MK; Ross JW; Mullins RF; Daley GQ; Schlaeger TM; Stone EM; Tucker BA
Mol Ther; 2017 Sep; 25(9):1999-2013. PubMed ID: 28619647
[TBL] [Abstract][Full Text] [Related]
15. Precision Therapy for Inherited Retinal Disease: At the Forefront of Genomic Medicine.
Koulisis N; Nagiel A
Clin Lab Med; 2020 Jun; 40(2):189-204. PubMed ID: 32439068
[TBL] [Abstract][Full Text] [Related]
16. Gene Editing for
Pierce EA; Aleman TS; Jayasundera KT; Ashimatey BS; Kim K; Rashid A; Jaskolka MC; Myers RL; Lam BL; Bailey ST; Comander JI; Lauer AK; Maguire AM; Pennesi ME
N Engl J Med; 2024 Jun; 390(21):1972-1984. PubMed ID: 38709228
[TBL] [Abstract][Full Text] [Related]
17. Correction of NR2E3 Associated Enhanced S-cone Syndrome Patient-specific iPSCs using CRISPR-Cas9.
Bohrer LR; Wiley LA; Burnight ER; Cooke JA; Giacalone JC; Anfinson KR; Andorf JL; Mullins RF; Stone EM; Tucker BA
Genes (Basel); 2019 Apr; 10(4):. PubMed ID: 30959774
[TBL] [Abstract][Full Text] [Related]
18. Guiding Lights in Genome Editing for Inherited Retinal Disorders: Implications for Gene and Cell Therapy.
Sanjurjo-Soriano C; Kalatzis V
Neural Plast; 2018; 2018():5056279. PubMed ID: 29853845
[TBL] [Abstract][Full Text] [Related]
19. Future Perspectives of Prime Editing for the Treatment of Inherited Retinal Diseases.
Hansen S; McClements ME; Corydon TJ; MacLaren RE
Cells; 2023 Jan; 12(3):. PubMed ID: 36766782
[TBL] [Abstract][Full Text] [Related]
20. Prime Editing for Inherited Retinal Diseases.
da Costa BL; Levi SR; Eulau E; Tsai YT; Quinn PMJ
Front Genome Ed; 2021; 3():775330. PubMed ID: 34901928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
